^
Association details:
| Biomarker: | EGFR positive |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CETUXIMAB PLUS IRINOTECAN IN PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER PATIENTS SELECTED ON THE BASIS OF KRAS MUTATION AND EGFR INTRON 1 CA TANDEM REPEATS: PHASE II PROSPECTIVE STUDY AND RETROSPECTIVE ANALYSES OF NEW POTENTIAL MOLECULAR PREDICTORS OF OUTCOME
Excerpt:
... EGFR-positive tumor at immunohistochemistry. ...
Trial ID:
Source:
Title:
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Excerpt:
......
Trial ID:
More C2 evidence
Source:
Title:
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
Excerpt:
...- Epidermal growth factor receptor status-positive, -negative, or -unknown...
Trial ID:
Source:
Title:
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Excerpt:
...- EGFR positive...
Trial ID:
Source:
Title:
Cetuximab and Best Supportive Care Compared with Best Supportive Care Alone in Treating Patients with Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer.
Excerpt:
...Histologically confirmed colorectal cancer- Metastatic disease- Epidermal growth factor receptor (EGFR)-positive by immunochemistry- Measurable or evaluable disease- Not amenable to standard curative therapy- Best supportive care is the only available option- Must have received a prior thymidylate synthase inhibitor (eg: fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) in the adjuvant or metastatic setting- Combination therapy with oxaliplatin or irinotecan allowed- Must have failed* a prior regimen containing irinotecan and a prior regimen containing oxaliplatin for metastatic disease OR relapsed within 6 months after an adjuvant regimen containing irinotecan or oxaliplatin OR have documented unsuitability for such regimens....
Trial ID:
Source:
Title:
Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
Excerpt:
...- Epidermal growth factor receptor (EGFR)-positive by immunochemistry...
Trial ID:
Source:
Title:
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
Excerpt:
...- Must have positive EGFr expression (tumor tissue) by immunohistochemical assay....
Trial ID:
Source:
Title:
Reactivating NK Cells in Treating Refractory Head and Neck Cancer
Excerpt:
...Histologically confirmed diagnosis of EGFR-positive nasopharyngeal carcinoma or EGFR positive HNSCC (based on >80% immunohistochemistry of biopsy of recurrent tumor Ventana (Roche) clone 3C6 3....
Trial ID:
Source:
Title:
Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Excerpt:
...- Primary tumor or metastases must be epidermal growth factor receptor-positive by immunohistochemistry...
Trial ID:
Source:
Title:
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma
Excerpt:
...Determine the response rate of cetuximab in patients with EGFR-positive, metastatic carcinoma...
Trial ID:
Source:
Title:
Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer
Excerpt:
...- Histologically documented colorectal cancer which is EGFR-positive by immunohistochemistry [IHC] (may be based on archival samples) and is metastatic....
Trial ID:
Source:
Title:
Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer
Excerpt:
...- Documented colorectal cancer which is EGFR-positive and is metastatic....
Trial ID:
Source:
Title:
A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
Excerpt:
...- Subjects with histologically or pathologically confirmed metastatic colorectal cancer, which is EGFR-positive by IHC (may be based on archival samples)...
Trial ID:
Source:
Title:
Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan in First-Line Treatment of Metastatic Colorectal Cancer
Excerpt:
...- Diagnosis of non-resectable, histologically confirmed, epithelial growth factor receptor(EGFR)-positive or negative colorectal cancer...
Trial ID:
Source:
Title:
Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer
Excerpt:
...- Immunohistochemical evidence or positive EGFR expression prior to study entry in primary tumor and/or at least one metastasis...
Trial ID:
Source:
Title:
Phase II., non randomized, open study: inoperable gall bladder or biliary tract EGFR expressing carcinoma treatment with Erbitux and 5-fluorouracil, epiadriamycin, mitomycin containing combination
Excerpt:
...EGFR positivity (IHC). ...
Trial ID:
Source:
Title:
Open labeled, multicenter phase I / II study evaluating the dose escalation/ safety of Cetuximab and Oxaliplatin/ 5-FU/FA/ Irinotecan as first-line treatment of metastatic colorectal cancer
Excerpt:
...For inclusion in the study, all of the following inclusion criteria must be fulfilled:- Diagnosis of non-resectable, histologically confirmed, EGFR positive or negative colorectal cancer - WHO PS 0 or 1- Signed written informed consent - ≥18 years of age- Effective contraception for both male and female subjects if the risk of conception exists- Adequate bone marrow function: Neutrophiles blood cell count (NBC) ≥ 1,5x109/L, platelet count ≥ 100x109/L, hemoglobin ≥ 5.96 mmol/L (10 g/dL)- Adequate liver and renal function: bilirubin ≤ 1,5 x upper normal level (UNL) and not increasing more than 25% within the last 4 weeks, ASAT and ALAT ≤ 5 x UNL. ...
Trial ID:
Source:
Title:
Klinische Studie für Patienten mit einer fortgeschrittenen Lungenkrebserkrankung mit zwei unterschiedlichen Behandlungsmethoden: Cisplatin oder Carboplatin mit Docetaxel in Kombination mit Cetuximab
Excerpt:
...- histologically or cytologically confirmed NSCLC stadium IV UICC 7 - life expectance more than 3 month - ECOG performance status 0 or 1 - positiv EGFR status (IHC score ≥200)...
Trial ID:
Less C2 evidence
Source:
Title:
Cetuximab-Polymersome-Mertansine Nanodrug for Potent and Targeted Therapy of EGFR-Positive Cancers
Published date:
02/04/2022
Excerpt:
Herein, we constructed a robust cetuximab-polymersome-mertansine nanodrug (C-P-DM1) for highly potent and targeted therapy of epidermal growth factor receptor (EGFR)-positive solid tumors. C-P-DM1 with a...6.0-11.3-fold stronger cytotoxicity in EGFR-positive human breast (MDA-MB-231), lung (A549), and liver (SMMC-7721) cancer cells (IC50 = 27.1-135.5 nM) than P-DM1 control....This robust cetuximab-polymersome-mertansine nanodrug provides a promising new strategy for targeted treatment of EGFR-positive solid malignancies.
DOI:
10.1021/acs.biomac.1c01065
